La Nación / Study published in the country on the vaccine

The results of the phase 3 study on the covid-19 vaccine, conducted in our country with professionals from the UNA Faculty of Medical Sciences, have been published in the prestigious medical journal Vaccine.

For the first time, a study on the phase 3 vaccine developed in Paraguay is published in the journal Vaccine, which they have highlighted as a real milestone for the field of medicine and research in our country.

It should be mentioned that this study was jointly conducted by professionals from the Faculty of Medical Sciences of the National University of Asuncion (FCM UNA) and the biotechnology laboratory Medigen Vaccine Biologics Corporation (MVC) in Taiwan.

The research is entitled “An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase 3, parallel group, randomized, double-blind study, with active control of immunosupply in Paraguay” and was conducted by dr. Julio Torales, co-authored by FCM UNA Dean, Dr. Osmar Cuenca Torres; Dr. Laurentino Barrios, Dr. Luis Armoa, Dr. Gladys Estigarribia, Dr. Gabriela Sanabria. Meei-Yun Lin, Josue Antonio Estrada, Lila Estephan, Hao-Yuan Cheng, Charles Chen, Rober Janssen and Chia-En Lien participated on behalf of Medigen Vaccine Biologics.

From the Faculty of Medical Sciences of the UNA, they underline the fact that an article of this magnitude is made available to the entire international scientific community through one of the most prestigious journals in the world of medicine such as Vaccine.

“This study demonstrates that our vaccine candidate is safe and immunogenic and that it works against covid-19, as well as demonstrating that as an institution, the UNA Faculty of Medical Sciences has a first-world research capacity,” said the Prof. Dr. Julito Torales, principal investigator.

The phase 3 study of the MVC-COV1901 vaccine conducted in our country – which lasted 8 months and involved approximately 1,030 randomized participants – concluded that previous infection together with vaccination with this platform may offer protection against the Omicron strain, although its duration is still unknown.

Anyone interested in reading the article published in Vaccine magazine can do so by visiting their website.